Celebrating 25 years Est 1999-2024
*Across 3 years $2158.56 only $1079.28
News) - GW Pharmaceuticals PLC Monday said it was focused on the approval of its flagship drug Epidiolex in childhood- ...
- Three Positive Phase 3 Epidiolex clinical trials reported in 2016 -- NDA submission and launch preparation...
AIM 05 December 2016 NOTICE 05/12/2016 7:00am NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIM GW PHARMACEUTICALS PLC At the request of the...
GW Pharmaceuticals PLC 01 December 2016 GW Pharmaceuticals plc Announces Epidiolex(R) (cannabidiol) Data Presentations and Educational Programs at...
- Presentations include clinical results from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet...
GW Pharmaceuticals PLC 30 November 2016 GW Pharmaceuticals to Report Q4 and Year-End Financial Results and Host Conference Call on 5 December...
LONDON, Nov. 30, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the...
GW Pharmaceuticals PLC 24 November 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 1. Identity of the issuer or GW Pharmaceuticals PLC the...
LONDON, Nov. 22, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the...
GW Pharmaceuticals PLC 22 November 2016 GW Pharmaceuticals to Present at the 28(th) Annual Piper Jaffray Healthcare Conference on 29 November...
GW Pharmaceuticals PLC 18 November 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 1. Identity of the issuer or GW Pharmaceuticals PLC the...
GW Pharmaceuticals PLC 11 November 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 1. Identity of the issuer or GW PHARMACEUTICALS PLC the...
News) - GW Pharmaceuticals PLC on Thursday said Non-Executive Director Thomas Lynch sold shares in the company earlier ...
GW Pharmaceuticals PLC 10 November 2016 Notification and public disclosure of transactions by persons discharging managerial responsibilities and...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.